Back

Molecular Partners AG

Molecular Partners AG is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics, a new class of custom-built drugs for medical challenges other modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zürich, Switzerland and Concord, MA, USA.

25/02/2025
Internship
Internship - Machine Learning & AI Bioinformatics M/F
Molecular Partners AG Schlieren, ZH, Switzerland
Information about Molecular Partners AG Founded in 2004 by a group of PhD students as a spin-off from the University of Zurich, Molecular Partners AG is a thriving and steadily growing clinical stage biotech company located in Zurich-Schlieren (Switzerland) with 180 highly qualified employees. In order to advance modern medicine and significantly improve the management of serious diseases, we have developed and successfully established a powerful new class of potent, specific and versatile small protein therapies, called DARPin therapeutics. The continuous development of a broad portfolio of therapeutic product candidates in oncology, radio-ligand therapy and ophthalmology based on the company’s proprietary DARPin platform allowed a successful listing of the company on the SIX Swiss Exchange and Nasdaq (ticker: MOLN). Next to our own pipeline of drug candidates we have entered into collaborations with leading international pharmaceutical companies, including...